Management of Functional Biliary Pain
For patients with functional biliary pain (biliary-type pain without gallstones), cholecystectomy should be considered only when Rome III criteria are met AND cholecystokinin-cholescintigraphy (CCK-CS) demonstrates a gallbladder ejection fraction (GBEF) <38% using the standardized 60-minute infusion protocol. 1
Diagnostic Criteria and Patient Selection
Rome III Criteria for Functional Gallbladder Disorder
Patients must have episodes of right upper quadrant and/or epigastric pain with ALL of the following characteristics: 1
- Episodes last at least 30 minutes 1
- Recurrent episodes occur at different intervals (not daily) 1
- Pain builds to a steady level 1
- Pain severe enough to interrupt activities or prompt clinical visit 1
- Pain NOT relieved by bowel movements, postural change, or antacids 1
- Other structural diseases excluded 1
- Gallbladder present with no gallstones on ultrasound 1
- Normal liver tests and pancreatic enzymes 1
Supportive Features
The pain may present with: 1
Mandatory Workup Before CCK-Cholescintigraphy
Before proceeding to CCK-CS, patients must undergo: 1
- Transabdominal ultrasonography to confirm absence of gallstones 1
- Liver function tests and pancreatic enzymes 1
- Upper endoscopy to exclude other causes 1
CCK-Cholescintigraphy Protocol
When to Perform
CCK-CS should only be performed in patients who: 1
- Meet Rome III criteria for functional biliary pain 1
- Are NOT currently experiencing pain 1
- Are NOT hospitalized at the time of study 1
- Are NOT taking interfering medications (opioids, calcium channel blockers, oral contraceptives, H2-receptor antagonists, benzodiazepines) 1
Standardized Testing Protocol
The only validated protocol uses: 1
- Sincalide dose: 0.02 μg/kg (total dose 1.4 μg for 70 kg patient) 1
- Infusion duration: 60 minutes (NOT shorter durations) 1
- Normal GBEF cutoff: ≥38% 1
- Abnormal GBEF: <38% is consistent with functional gallbladder disorder 1
Treatment Algorithm
For GBEF <38% with Rome III Criteria
Cholecystectomy is recommended, as current expert consensus favors surgery for patients with biliary pain and abnormal GBEF. 1 However, the evidence base remains limited and a large prospective randomized controlled trial is still needed. 1
For GBEF ≥38% or Atypical Symptoms
Cholecystectomy should NOT be performed. 1 Patients with atypical symptoms (indigestion, flatulence, heartburn, bloating, belching, nausea alone) are less likely to benefit from cholecystectomy, and CCK-CS does not add to clinical judgment in predicting surgical outcomes for these patients. 2
Critical Pitfalls to Avoid
Patient Selection Errors
Do NOT perform CCK-CS in patients with: 1
- Atypical symptoms that don't meet Rome III criteria 1
- Active pain at time of testing 1
- Use of interfering medications 1
An abnormal GBEF is NOT specific for functional gallbladder disorder and may occur in: 1
Technical Errors
Do NOT use non-standardized protocols. 1 Infusion durations shorter than 60 minutes, different doses, or bolus administration produce unreliable results that cannot be compared to validated cutoff values. 1
Interpretation Errors
CCK-induced pain during the test does NOT have proven diagnostic value and should not be used to guide treatment decisions. 1 The development of symptoms following sincalide infusion may not reflect the presence of gallbladder disease. 1
Anatomic Considerations
The gallbladder may not be responsible for a decreased GBEF. 1 Occasionally, outflow obstruction from cystic duct abnormalities or sphincter of Oddi dysfunction may be the actual cause. 1
Expected Outcomes
Approximately 30% of patients with a single episode of biliary pain may not experience additional episodes even without treatment. 2 This natural history should be discussed with patients when considering cholecystectomy for functional biliary pain.
Persistent dyspeptic symptoms occur frequently following cholecystectomy in patients with atypical presentations. 2 A prolonged history of dyspeptic symptoms prior to surgery predicts unsatisfactory surgical outcomes. 3